Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2004 April;139(2) > Giornale Italiano di Dermatologia e Venereologia 2004 April;139(2):97-109

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

A Journal on Dermatology and Sexually Transmitted Diseases


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,311


eTOC

 

REVIEWS  


Giornale Italiano di Dermatologia e Venereologia 2004 April;139(2):97-109

Copyright © 2004 EDIZIONI MINERVA MEDICA

language: English, Italian

Immunoterapy of malignant melanoma and adjuvant therapies

Satriano R. A. 1, Di Girolamo F. 1, Ascierto P. A. 2, Scala S. 2, Ottaiano A. 2, Castello G. 2, Ruocco V. 1

1 Department of Dermatology, Second University of Naples, Naples 2 Department of Clinical Immunology National Cancer Institute, Naples


PDF  


Biotherapies, including immunotherapy, are a field of great interest in the treatment of malignant melanoma and many new approaches have been proposed in the last years. The aim of this paper is to review the literature on immunotherapies (vaccines, cytokines, adjuvant immunotherapies) in the treatment of malignant melanoma. There is a wide diversity in contents and quality of studies. Frequently, the therapies are proposed for advanced disease as the “last chance” for the patients. Hopefully, quality of the studies could be improved by selecting a priori patients bearing a particular target with not heavily pretreated disease and by evaluating biological end-points.

top of page

Publication History

Cite this article as

Corresponding author e-mail